Home/Eliksa Therapeutics/Garrett Vygantas, MD

GV

Garrett Vygantas, MD

Board Member

Eliksa Therapeutics

Therapeutic Areas

Rare Diseases Ophthalmology Dermatology

Eliksa Therapeutics Pipeline

Drug	Indication	Phase
ELK-003	Ocular manifestations of Epidermolysis Bullosa (EB)	Pre-clinical/Early Clinical

Leadership Team at Eliksa Therapeutics

Armen Karamanian, MD, PhD

Co-Founder & CEO

Jane Hollingsworth

Co-Founder & Executive Chairman

View full Eliksa Therapeutics profile